Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Recruiting

• Conditions: Marginal Zone B Cell Lymphoma

• Registration Number: NCT06806488
• Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Brief Summary

This is a purely retrospective and observational monocentric study

Detailed Description

the study aimed at describing the characteristics and outcome of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018

Study Timeline

• Status Verified: 2024-10
• Study First Submitted: 2024-12-03
• Study First Submitted QC: 2025-01-28
• Last Update Submitted: 2025-01-28
• Study First Posted: 2025-02-04
• Last Update Posted: 2025-02-04
• Study Start: 2025-05
• Primary Completion: 2025-10
• Study Completion: 2025-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

1. Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018.
2. Age ≥ 18 years at enrolment.
3. Written informed consent (if applicable)

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
clinical characteristics of Marginal zone lymphoma patients	through study completion, an average of 1 years	to descrive clinical characteristics of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital.

Secondary Outcome Measures

Name	Time	Method
effectiveness	through study completion, an average of 1 years	It includes: 1. Description of treatment duration and causes of treatment discontinuation.; 2. Description of adverse events / safety of the treatments; 3. Assessment of patients' survival.; 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions.; 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases
safety	through study completion, an average of 1 years	It includes: 1. Description of treatment duration and causes of treatment discontinuation.; 2. Description of adverse events / safety of the treatments; 3. Assessment of patients' survival.; 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions.; 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases

Trial Locations

Locations (1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna; 🇮🇹 Bologna, Italy